An impressive 30% growth in H1 (for the third consecutive 6 month period), with strong performance from across both revenue generating divisions, and a very confident outlook statement, supports our BUY recommendation. MaxCyte’s enabling technology has wide application in both drug discovery and cell therapy. In addition, development of its own CARMA cell therapy program continues to progress to plan. We retain our BUY recommendation and 170p price target
